drugset / Trial / NCT02636699

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

NCT02636699 ↗

Phase 3 Completed 500 enrolled DBV Technologies
RandomizedParallel-groupTriple-blindTreatment

Summary

The PEPITES study evaluates the efficacy and safety of Viaskin Peanut 250 µg peanut protein to induce desensitization to peanut in peanut-allergic children 4 through 11 years of age after a 12-month treatment by epicutaneous immunotherapy (EPIT).

Timeline

Start
2015-12
Primary completion
2017-08-18
Completion
2017-08-18

Outcome

Missed primary endpoint

paper The prespecified lower bound of the CI threshold was not met. PMID 30794314 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Viaskin Peanut Protein / enzyme biologic 250 ug Topical

Indications